PAPALPosaconazole Levels in Lung Transplant Recipients for Infection Prevention

This study focuses on lung transplant recipients, specifically those with and without cystic fibrosis (CF). The main goal is to understand how a drug called posaconazole behaves in their bodies, particularly in the plasma and the alveolar compartment (AC) of the lungs. Posaconazole is an antifungal medication given routinely after transplantation to prevent fungal infections. By studying its behavior, the research aims to improve post-transplant care and reduce the risk of fungal infections in these patients. During the study, participants receive posaconazole as part of their routine post-operative care. To measure the drug's concentration, samples are taken from both the plasma and the lungs during any clinically-indicated bronchoscopy, a procedure where a thin tube is inserted into the lungs. Participants may have more than one bronchoscopy. Additionally, blood samples are collected approximately 4 hours after the first daily dose on Days 1-12 and every Monday and Thursday on Days 13-43. These samples help determine the time it takes for the drug to reach 90% of its steady state concentration in the serum, providing valuable insights into how quickly the drug becomes effective.